What to Expect

Once patients and their providers discuss and decide to pursue enrollment and select a phase 1 trial, the patient will be screened by study staff to see if their characteristics fit the eligibility criteria of the trial.5 During this process, the study staff explain the clinical trial, including what is being studied and what is required of the patient.1 Patients have the opportunity to ask questions. Patients who wish to continue with the enrollment process at this time are asked to sign a consent form, which states that the patient was informed of the potential risks and benefits of the trial, and that their questions were answered.

Patients may want to ask questions about the treatment and/or tests that are required, how the experimental therapy compared with standard treatments, the possible side effects, how long the trial may last, what the time commitment is expected to be, and who will be in charge of their medical care.

Continue Reading

After consenting to participate, patients are screened to ensure that they fit the eligibility criteria.1 The inclusion criteria vary for different studies, but may include age, stage of disease, family history, or genetic profile, and exclusion criteria—which typically bar patients from participating based on circumstances such as the existence of prior or current health conditions other than the cancer, or the receipt of certain medications in the past.

Patients who meet the inclusion criteria will then undergo baseline testing.1 This could be laboratory testing and/or molecular testing. Then, patients will begin their assigned experimental treatment.

During treatment, patients will return to the study site for follow-up visits, where additional testing may be performed to monitor for specific side effects and, in some cases, efficacy.1,8 The study staff also evaluate the patient for any symptoms of side effects.

Related Articles

If a side effect develops, it will be treated according to the current standard of care and does not necessarily mean that the patient will have to stop the experimental drug or leave the trial.8 This is determined based on the type of side effect observed and its severity.

Patients can continue the experimental therapy and participate in the phase 1 trial for as long as they benefit from that treatment, with many phase 1 trials lasting about 2 years.8 If a patient’s disease progresses during the trial, they typically will discontinue the experimental therapy and either enroll in another clinical trial, switch to another treatment outside of a clinical trial setting, or elect to enter hospice.


  1. National Institutes of Health. National Institute on Aging. What are clinical trials and studies? Updated May 17, 2017. Accessed March 3, 2020.
  2. Weber JS, Levit LA, Adamson PC, et al. American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. J Clin Oncol. 2015;33:278-284.
  3. Adashek  JJ, LoRusso PM, Hong DS, Kurzrock R. Phase I trials as valid therapeutic options for patients with cancer. Nat Rev Clin Oncol. 2019;16:773-778.
  4. Wong KM, Capasso A, Eckhardt SG. The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol. 2016;13:106-117.
  5. Mahipal A, Nguyen D. Risks and benefits of phase 1 clinical trial participation. Cancer Control. 2014;21:193-199.
  6. Italiano A, Massard C, Bahleda R, et al. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol. 2008;19(4):787-792.
  7. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005;352:895-904.
  8. Carter D. Q&A: Phase I clinical trials. The University of Texas MD Anderson Cancer Center. Published November 16, 2016. Accessed March 3, 2020.
  9. Huey R, George G, Philips P, et al. Out-of-pocket costs and financial toxicity experienced by patients in early-phase clinical trials. J Clin Oncol. 2019;37(suppl 15; abstr e18383).
  10. Kimmelman J. Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine. Nat Rev Clin Oncol. 2019;16(12):719-720.